• Emaginos is committed to solving two major education problems
• Investing in Emaginos provides an opportunity to do good and do well, says company president
• Company plans to transform America’s public schools to a more effective model based on a carefully integrated set of proven best practices

Emaginos, a company raising new capital under provisions of Regulation A of the Securities Act of 1933 (please see website if interested in investing), is seeking $3 million to begin the transformation of the K-12 education system in the United States. Based on the company’s proprietary Discover Learning System (“DLS”), Emaginos offers investors an opportunity to attempt to realize return on their investment while fixing one of the nation’s fundamental problems — its educational system.

Emaginos is committed to solving two major problems, according to a recent President’s blog (https://ibn.fm/xhXyg). “The first is fixing . . . the outdated and test-bound K-12 public school system,” writes Emaginos president Allan Jones. “The second is enabling teachers and parents to benefit financially from the transformation – doing good while doing well.”

Jones explains what doing good while doing well means: “Doing good refers to behaving altruistically or charitably. Doing well refers to being financially secure,” he writes. “Looking at Maslow’s Hierarchy (https://ibn.fm/UZisi) tells us that instinctually we have to focus on doing well before we can consider doing good. Investing in Emaginos provides an opportunity to do both simultaneously.”

In his blog, Jones notes that “you don’t need to be a researcher to be aware that America’s public schools are failing to meet the 21st-century educational needs of our children and, therefore, of our country’s future. The current lack of digital and educational equity inherent in America’s K-12 public education system is a shameful disgrace. The ‘teach-to-the-test’ and related reliance on high-stakes testing is turning off our children and driving dedicated teachers from their chosen profession. At the same time, profiteers and elected officials have realized they can use (or abuse) our schools for their financial or political gain.

“Along comes Emaginos,” Jones continues. “Our plan is to transform America’s public schools to a more effective model based on a carefully integrated set of proven best practices. Note that we are not seeking to create more charter schools. We are not seeking to take over and operate schools. We are not seeking to eliminate teachers’ unions.”

So what is Emaginos’s strategy?

Emaginos uses existing facilities, staff, students and faculty, explains Jones. “We provide them a comprehensive transformational suite of services and resources that enable the local schools to become engaging learning environments producing entrepreneurial lifelong self-directed learners. Teachers run the schools.”

As far as cost, Emaginos products and services require an initial cost to develop, but once developed, they can be sold many times at very low incremental cost. “The first schools will break even,” Jones explains. “Subsequent schools or districts will provide the same revenue but cost progressively less to transform and support. Any profits will enable Emaginos investors to potentially realize a return on their investments as we continue to improve our products and services and grow the business.”

The opportunity to both earn a profit and fix a fundamental problem in the country today is an unusual proposition in the world of investing. Jones’s invitation is simple: “If you are interested in joining us in doing good for our students while possibly realizing a return on investment, go to https://Emaginos.com/reasons-to-invest to learn more.”

For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com.

NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
• Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
• The company is positioned to engage several markets, including digital therapeutics and research

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (https://ibn.fm/xOXo9).

Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes. We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of the pharmaceutical-grade product.”

Ibogaine is a psychoactive substance that can be found naturally in the roots of the African iboga tree. The company is actively researching ibogaine as a potential treatment for traumatic brain injury and other related conditions. All preliminary data show that the drug may also yield promising results as a treatment for neuropathic pain and migraines. In addition, research also indicates that ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addiction.

MINDCURE has filed U.S. provisional patent applications for two routes of chemical synthesis of ibogaine. Both routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds. Both are currently under assessment to determine the preferred method for further developing the compound (https://ibn.fm/ojpg5).

Chief Medical Officer Joel Raskin discussed the natural iboga plant as a precious resource, stating, “Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy. Our company’s research team would also have access to this sustainable drug supply.”

MINDCURE is positioned to disrupt several different market spaces through its technology, research, and products, including the digital therapeutics space, which covers health interventions delivered through a smart device to induce a behavioral change in the patient. The company’s leading foray into the digital therapeutics space is iSTRYM, an AI-driven software platform that enables personalized and calculated outcomes in psychedelic therapy.

The global digital therapeutics market was valued at $2.88 billion in 2019, but it is expected to reach $13.8 billion by 2027 with a CAGR of 20.5% during the forecast period (https://ibn.fm/793EJ). The global market for drug addiction therapy, where ibogaine can be a potential game changer, was valued at $17.65 billion in 2019 and is expected to grow at a CAGR of 7% during the forecast period, resulting in a value of $31.17 billion by 2027 (https://ibn.fm/oAI5T).

For more information, visit the company’s website at www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Brain-Computer Interface (“BCI”) market is expanding rapidly, expected to double to USD 406 billion by 2026
• BCI technology, designed to acquire brain signals, analyze and translate them into commands, is one of key driving forces behind EEG technology growth
• Brain Scientific appears poised to capitalize on this novel technology as its applications expand from medical settings to training, consumer engagement, entertainment, and more

The Brain-Computer Interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. As the provider of EEG technology, Brain Scientific (OTCQB: BRSF) appears well placed to leverage this rapid growth of the industry expected to double in size by 2026 (https://ibn.fm/F5LOs).

BCI technology refers to solutions that record the brain signal from the surface of the cortex, using sensors placed over the scalp or signaling devices implanted in the brain. As a promising approach to overcome paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector, BCI can provide opportunities for motor rehabilitation from a number of conditions, including spinal cord injury, traumatic brain injury, and stroke (https://ibn.fm/C9Dom). This powerful technology can even help patients who lost the ability to speak to communicate. A recent study reports the first patient ever to produce whole words via a computer that decodes his brain’s messages through electrodes implanted in his brain (https://ibn.fm/gr3j7).

Enabling advances never possible before, the BCI space is expanding rapidly, and EEG is an essential part of that landscape. Recent market research reveals that the BCI market is expected to grow at a 12.4% CAGR over the next five years, reaching $409.3 million by 2026 — more than double compared to $203 million reported in 2020. Main growth drivers include swelling demand from healthcare, entertainment, gaming, communication, and control.

Traditionally, EEG-based BCI technology has been geared towards medical applications where it was utilized to help disabled patients to interact with the external world. However, with a shift of focus towards people with normal health, the technology is no longer constrained to medical settings only. For example, training — including athletic, military, and occupational — and fields such as consumer engagement and entertainment are becoming target groups that would likely benefit from using EEG-based BCI systems (https://ibn.fm/oV87E).

As the application space for EEG-based BCI solutions expands, Brain Scientific appears poised for rapid growth. With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the Company appears well-placed within the growing brain monitoring space. Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the ground-breaking technology that aim to enable what was inconceivable until recently.

For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• FingerMotion’s SMS & MMS, TPS, and Big Data divisions generated $6.00 million in revenue for Q1 2022
• The SMS & MMS and TPS businesses’ Q1 2022 revenues increased significantly compared to Q1 2021 figures
• Q1 2022 also marked the second consecutive quarter in which the big data division generated revenue, and a Q/Q increase at that
• FingerMotion is also targeting the accretive rich communications services (“RCS”) segment, with RCS expected to form its fourth division

On July 15, evolving technology company FingerMotion (OTCQX: FNGR) released its Q1 2022 results in which it reported record quarterly revenue of $6.00 million, generated by its SMS & MMS, Telecommunications Products & Services (“TPS”), and Big Data divisions. The SMS & MMS division’s revenue was up 77% or $1.81 million compared to Q1 2021, while the TPS division’s revenue grew by 341% or $1.34 compared to a similar period a year before (https://ibn.fm/S1osq).

Q1 2022 also marked the second consecutive quarter of revenue from the Big Data division with reported revenue of $98,715. This figure represented a 198% quarter-over-quarter increase, given that in Q4 2021, the division generated $33,077.

“Growth continues to be fueled by an expansion of subscribers in new regions along with larger purchases of SMS from our corporate clientele,” commented FingerMotion CEO Martin Shen. “This is the second consecutive quarter of Big Data revenues, and we expect it to continue and eventually outpace our existing revenue streams.”

The Q1 2022 results’ announcement followed on the heels of the June 2 release of the company’s financial results for the fiscal year ended February 28, 2021. Here, FNGR reported that its SMS & MMS business and TPS division posted annual revenue growths of $6.13 million (84%) and $1.39 million (76%), respectively, compared to the previous financial year. The two businesses cumulatively contributed to a record annual revenue of $16.68 million (https://ibn.fm/ml4Fh).

FingerMotion anticipates that if the current trajectory defined by the Q1 2022 results continues, its revenue for FY 2022 may exceed $24 million, which would represent a year-over-year jump of over 44%. The projected increase is likely to result from its existing operations, suggesting that the SMS & MMS, TPS, and Big Data businesses will continue soaring throughout the remainder of FY 2022.

Meanwhile, FNGR is also targeting another high growth opportunity in rich communication services (“RCS”), expected to form the company’s fourth division.

Rich communication services are emerging as a formidable technology enabling users to access various advanced capabilities from their native messaging service without installing a third-party application. Such capabilities include group chat, video calling, file sharing, and even additional features such as the ability to book a restaurant or flight. RCS has revolutionized text-based messaging by eliminating previous constraints that limited it to merely sending short text messages. With RCS, messaging has become a platform (https://ibn.fm/pfZPX).

MarketsandMarkets projects that the global RCS market will grow from $5.2 billion in 2020 to $11.7 billion by 2025, representing a CAGR of 17.6% CAGR. The Asia Pacific (“APAC”) region is expected to record the highest growth rate during the forecast period, with China playing a dominant role as a key contributor to the growth. The study credits the region’s increasing populations, advanced SMS systems, expanding retail industry, rise in smartphone usage, and growing mobile payments for being behind the growth (https://ibn.fm/PVlm3).

FingerMotion identified the accretive opportunities within the emerging RCS segment and, in March 2020, allocated resources for the R&D of a proprietary RCS platform. “This RCS platform is expected to be a proprietary business messaging platform that enables businesses and brands to communicate and service their customers on 5G infrastructure, delivering better user experience, more efficiently and cost-effectively. This is expected to open up a new marketing channel for the company’s current and prospective business partners,” reads a segment from FingerMotion’s annual report filed with the SEC as form 10-K (https://ibn.fm/Elhme).

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Epic stage production features a unique end-of-the-world theme
• Company is curating a theme to create a ground-breaking production
• With more than 30,000 national followers, EpicRaves is on its way to achieving goal of becoming nationally recognized concert production company

Golden Triangle Ventures (OTC: GTVH) is making company history with the announcement of its debut event series: Armageddon (https://ibn.fm/5vKmz). This epic stage production features a unique end-of-the-world theme and is the company’s first-ever offering of this kind.

“We will deploy the largest Hennessy Sound Design system Las Vegas has ever seen in history for this amazing event, and we are going to curate a theme to our epic production unlike anything we have ever done in the past,” said GTVH CEO Steffan Dalsgaard. “Most of the headliners on our lineup have never played for this city, and we are so excited to debut our new Armageddon event this September.”

The series, slated for Sept. 17, 2021, at the Sahara Event Schedule, is presented by GTVH’s wholly owned subsidiary Lavish Entertainment (dba EpicRaves). The headliner performer for the event is MUST DIE! with Oddprophet making his U.S. debut. Others performing during the event include Au5, BeardThug, DirtySnatcha, Psymbionic and Sky Suite, as well as Drezza, Ethyrial, Mutavore, Meek, Channel 0, Killawolf, Vairix and Dub Sum Damage.

Dedicated to producing high-quality bass music events in Vegas, one of the world’s best-known entertainment destinations, EpicRaves enhances its ground-breaking performances with custom stage and sound design, state-of-the-art venues and touring DJs from around the world. The company is focusing on creating a fun, entertaining environment for the electronic dance music (“EDM”) community where fans can freely express themselves and where the quality of the event is paramount. With more than 30,000 national followers, the company is on its way to achieving its goal of becoming a nationally recognized concert production company.

Lavish Entertainment is also working to build an immersive virtual reality platform to help monetize its live-streamed concerts and assist its business in expanding into markets outside of Las Vegas. In addition, the company recently unveiled Syndicate Bass Records, its own record label that showcases some of the best bass music artists in the world.

Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• Nextech Founder and CEO Evan Gappelberg will present at the OTCQB Venture Virtual Investor Conference, scheduled for August 5, 2021, and later at the Jefferies Software Conference to be held September 14 to 15, 2021
• Earlier this year, Evan presented at a Virtual Investor Conference, wherein he highlighted the company’s plans, some of which it has already implemented
• Thus, during the upcoming conferences, which will bring together companies and investors, attendees can expect to learn more about Nextech, its core business, expectations, and more

Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), one of the leaders in the rapidly growing augmented reality (“AR”) industry, recently announced that Founder and CEO Evan Gappelberg will present at two upcoming conferences geared towards bringing companies and investors together.

On August 5, 2021, starting from 9.30 AM ET, Evan will present at the OTCQB Venture Virtual Investor Conference. The live and interactive online event organized by Virtual Investor Conferences (“VIC”) and beamed live on VirtualInvestorConferences.com will feature favorite venture companies traded on the OTCQB (https://ibn.fm/jACO2).

A premier proprietary investor conference series, VIC provides an interactive forum for publicly traded companies to discuss their businesses and investment stories, in addition to answering questions from investors. As a live, online event under the VIC umbrella, therefore, the OTCQB Venture Virtual Investor Conference will not be an outlier. It will promote interactivity by allowing investors to ask companies questions in real-time. The organizers will also make available an archived webcast of the presentations after the event.

Similarly, Evan will present and host 1×1 meetings at the annual Jefferies Software Conference scheduled for September 14 to 15, 2021. Aimed at addressing both near- and long-term investment opportunities, as well as discussing current trends in the United States and beyond, the upcoming event will bring together public and private software companies, leading executives, institutional investors, venture capitalists (“VCs”), and private equity investors. It will feature 1×1/small group meetings, company presentations, fireside chats, and panels (https://ibn.fm/hhmbi).

These two presentations will come just a few months after a February 4 precursor (https://ibn.fm/HlFcV) – which was also a VIC event – during which Evan outlined Nextech’s progress up until that point and expectations for 2021, including planned product and technology launches, as well as its revenue forecast.

“Before we get started with the presentation, I just want to put a little context into the presentation. In 2019, we generated $6 million in revenue. In 2020, we preannounced our revenue as $20 million, and in 2021, we are estimating $50-$60 million in revenue,” Evan began (https://ibn.fm/zHpiq). He then went on to describe “catalysts” for the company beyond revenue, which mainly revolved around expected technology launches within its AR division. These included a proprietary Ad Network and a live holoportation feature on its AirShow App.

Nextech has since launched these two technologies in addition to others, such as LiveX, its digital experience platform (“DXP”) released May 12, and EdTechX, a higher education solution built on Microsoft Azure and available on the LiveX platform.

If the earlier VIC presentation is anything to go by, attendees at the two upcoming conferences can expect to gain more insight into Nextech, its expectations for the future, and the progress it will have made up until then. They can also expect to learn more about AR, Nextech’s core business, present and emerging technologies that will support AR, and more.

For more information, visit the company’s website at www.NextechAR.com.

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• NOAA predicts above-average 2021 storm season
• SGTM wholly owned subsidiary provides unparalleled services, including commercial property storm recovery, tree trimming, clean up
• Company’s management team deploys its mobile command center, strategized with national partners to provide much-needed services

The National Oceanic and Atmospheric Administration (“NOAA”) Climate Prediction Center is anticipating an above-normal Atlantic hurricane season in the coming months (https://ibn.fm/GNdk1). NOAA forecasters are predicting a 60% chance of an above-normal season, a 30% chance of a near-normal season, and a 10% chance of a below-normal season. The Sustainable Green Team (OTC: SGTM) and its wholly owned subsidiary National Storm Recovery LLC are experts at dealing with the aftermath of storms, regardless of their severity.

“For 2021, a likely range of 13 to 20 named storms (winds of 39 mph or higher), of which six to 10 could become hurricanes (winds of 74 mph or higher), including three to five major hurricanes (category 3, 4 or 5; with winds of 111 mph or higher) is expected,” announced the Climate Prediction Center, noting that the predictions, which cover the hurricane season from June 1 through Nov. 30, come with a 70% confidence rating. “Now is the time for communities along the coastline as well as inland to get prepared for the dangers that hurricanes can bring.”

The Sustainable Green Team, through National Storm Recovery, offers the kind of expert support and guidance that communities may be looking for in order to prepare for and clean up after severe storms. For the past four decades, National Storm Recovery has provided unparalleled services, ranging from commercial property storm recovery to tree trimming and clean up (https://ibn.fm/N8aEf).

National Storm Recovery is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors. National Storm Recovery and its expert team of providers is committed to do all it takes to ensure properties are safe and that business can continue as usual.

In addition to superior storm recovery assistance, the company also offers tree removal, stump grinding, tree care, land clearing and grapple hauling. National Storm Recovery received the Angie’s List Super Service Award in 2018, and the company remains committed to providing superior next-level tree service to all who need it.

The Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation.

The company’s solutions are founded in sustainability and based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients.

To learn more about Sustainable Green Team Ltd., view the company’s investor presentation at https://ibn.fm/etElq.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Company executed record quarter by focusing on profitable operations, accretive acquisition of Homegrown Oregon
• Chalice posts record quarterly revenue, gross profit numbers
• Homegrown chain of five stores joined the Chalice brand earlier this year

Chalice Brands (CSE: CHAL) (OTCQB: CHALF) has released its 2021 second-quarter unaudited financial, noting highest-ever quarterly revenues, along with other promising numbers (https://ibn.fm/JETHJ). The company is a premier consumer-driven company specializing in the retail, production, processing, wholesale and distribution of cannabis.

“We are immensely proud to execute another record quarter by focusing on profitable operations and the accretive acquisition of Homegrown Oregon,” stated Chalice CEO and president Jeff Yapp “The integration of Homegrown and the adoption of our vertical products within the new stores is ahead of schedule. The staff are highly engaged and motivated to be part of the Chalice family. The whole team is energized and focused on growth as we showcase our brand portfolio nationally and remain dedicated to our ‘crawl-walk-run’ strategy.”

In the release, Chalice reported quarterly revenues from continuing operations of $6.8 million, a record high for the company and a 23% year-over-year increase compared to $5.5 million for the same period in 2020. Other impressive numbers for the quarter included an 82% increase in estimated gross profit. For Q2 2021, the company totaled $3.1 million, which represents a 46% gross profit margin compared to $1.7 million, or 37% gross profit margin rate in 2020. The company attributed the gross margin improvements to increased sales of vertical, in-house products manufactured by Chalice and increased third-party processing revenues.

“We will seek to continue our growth both organically and through any opportunistic and accretive transactions we may be able to execute upon,” said Chalice executive chairman John Varghese.

In May 2021, the company finalized its 100% ownership of SMS Ventures LLC, known as Homegrown Oregon, a chain of five retail dispensaries located in Portland, Salem and Albany, Oregon (https://ibn.fm/aIJiA). “The completion of this transaction increases our retail store footprint to 12 locations in the state of Oregon, supported by our own award-winning cultivation operations, our production facilities in Portland and our internal wholesale team covering the state,” said Yapp. “Chalice has set a target to achieve 5% market share in Oregon while we grow in other markets. Homegrown helps us progress toward that goal.”

Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with twelve dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California.

For more information, visit the company’s website at www.ChaliceBrandsLtd.com.

NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability
• The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption
• The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses
• The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants

Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses.

Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s news release (https://ibn.fm/H4wBZ).

Lexaria aims to make drugs more bioavailable through DehydraTECH conversion without impairing the drugs’ essential functions. Many antiviral drugs currently available experience a decrease in bioavailability when taken orally because of poor intestinal uptake and/or significant liver biotransformation within the patients’ bodies — the company cites the anti-inflammatory drug colchicine, which has a bioavailability of about 45 percent and a narrow margin between what is regarded as safe and toxic dosing.

Lexaria’s three primary objectives in testing DehydraTECH’s processing of colchicine and four other anti-inflammatories — darunavir, ebastine, efavirenz and remdesivir — were to determine if DehydraTECH processing would demonstrate evidence of increasing absorption through oral delivery, evidence that the drug compounds would continue to inhibit viruses as expected in mammalian cells, and evidence that the processing would not lead to the creation of new molecular entities (“NMEs”) requiring new regulatory approvals.

The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVD-19, HIV/AIDS or other infectious disease-causing viruses, according to the company, with the ultimate aim of forming partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics.

The five drugs being analyzed in conjunction with DehydraTECH processing are representative of protease inhibitors (“PIs”), reverse transcriptase inhibitors (“RTIs”) and a tubulin polymerization and microtubule inhibitor (“TPMI”) used to treat HIV, hepatitis C, hepatitis B, COVID-19 infections and cancers. Lexaria hopes to apply its discoveries to pharmaceuticals that fight other virus-triggered diseases such as shingles, influenza and viral forms of gastroenteritis, hepatitis, meningitis, and pneumonia.

The company’s news release cites statistics noting that 37.7 million people are currently known to be infected with HIV and 36.3 million people have died from HIV/AIDS since the beginning of the epidemic, between 290,000 and 650,000 people die every year from virus-driven seasonal influenza, and over 189 million people have been infected by SARS-CoV-2 in the current global epidemic with more than 4 million of them killed by the illness.

Vaccines have helped reduce the incidence and mortality of these viral illnesses, but effective oral delivery has the potential to increase the availability of medications where vaccines cannot be widely administered. Additionally, in each of the antiviral drug classes currently being tested, the outcomes in animals have demonstrated up to a three-fold increase in bioavailability to the bloodstream over established methods, which may ultimately prove a means of reducing the costs of administration.

“We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network in a June report (https://ibn.fm/OTtde). “Our delivery from oral to the bloodstream is as little as two minutes. We’re outrageously fast for oral technology,” Bunka stated.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
• Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022
• Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection

Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://ibn.fm/wO76R).

The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the bladder wall. Yet, it is almost impossible to detect and resect cancerous cells that lay flat against the bladder, leaving some cells behind and causing a higher risk of recurrence. Approximately 50% of patients who have had a cystoscopy to remove NMIBC see their cancer return. Right now, approximately 724,000 people are living in fear that their bladder cancer will come back (https://ibn.fm/Ker0P).

Blue Light Cystoscopy (“BLC”), used with and FDA approved imaging agent that fluoresces the cancer cells, was introduced in 2010.  Although proven to be more effective in identifying cancerous cells and reducing recurrence, blue light is still only used in approximately 10% of bladder cancer procedures due to training, cost and ease-of-use issues.

To address these issues,  Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings.

Imagin Medical’s technology has entered the manufacturing stage with the company’s partner, Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022.

With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder cancer visualization by radically changing how cystoscopies are performed and ultimately helping improve patients’ lives and long-term outlook. Imagin Medical’s target is estimated to be a $400M portion of the global endoscopy market valued at $25.59 billion in 2019 and is expected to grow at a CAGR of 6.6 percent to reach a total estimated value of $35.23 billion by 2024 (https://ibn.fm/5jNuO).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF